Sero-protection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan

M. Rezaei¹, S. NooriPooR¹, R. GhORBani¹, F. RamEZAnShAMS¹, S. MamISH², S. MahMOUDI³

¹ Department of Pediatrics, Amir Almomenin Hospital, Semnan University of Medical Sciences, Semnan, Iran; ² Department of Pediatrics, Children Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran; ³ Pediatric Infectious Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Key words
Hepatitis B antibody • Vaccination • Children

Summary

Introduction. There are controversies over the long-term persistence of post vaccination immunity to hepatitis B and the need for booster doses of the vaccine. The aim of this study was to verify antibody levels of antibody against hepatitis B virus surface antigen (anti-HBs) in children aged 1 to 15 years who received vaccination against hepatitis B in the central province of Iran, Semnan.

Materials and methods. We performed a seroepidemiological survey (n = 210) of anti-HBs in 2011 in the central province of Iran. Semnan using enzyme-linked immunosorbent assay (ELISA). The levels of anti-HBs < 10 mIU/mL were considered to be negative and samples showing an anti-HBs titer ≥ 10 mIU/mL was considered protective.

Results. Protective antibody levels were detected in 88% of the children less than 5 year after vaccination, decreased to 78% between 5 to 10 years after vaccination, and further declined to 74% in 10 years after vaccination, respectively.

Conclusion. The vaccination program has been proven effective in Semnan and immunological protection against hepatitis B infection was found in the majority of children even more than 10 years after being vaccinated.

Introduction

The vaccine against hepatitis B virus (HBV) is included in the routine immunization schedule for children in most countries with the ultimate goal of reducing the prevalence of chronic hepatitis B carriers, as well as preventing the occurrence of acute hepatitis B [1]. Although long-term reduction of chronic HBV after hepatitis B vaccination has been reported [2], decreasing the levels of antibody against hepatitis B surface antigen (anti-HBs) over the time can be alarming [3].

Hepatitis B virus (HBV) prevalence has decreased dramatically in Iranian population since 1993 when the mass vaccination program was started. The geographic distribution of HBV infection in Iran showed heterogeneous patterns of HBV prevalence from the highest prevalence rates of more than 3% in northeastern region of our country to less than 2% in central and western regions of Iran [4].

Several hundred million doses of plasma-derived HB vaccines are produced in the Republic of Korea, China, Vietnam, Myanmar, India, Indonesia, Iran and Mongolia [5, 6]. Engerix-B® (SmithKline Beecham, 1992) and Recombivax HB® (Merck & Co.) are considered as the two major yeast-derived hepatitis B vaccines that are licensed in most countries [5].

There are controversies over the long-term persistence of post vaccination immunity to HBV and the need for booster doses of the vaccine [7].

Materials and methods

In this cross-sectional study, all children between ages of 1 and 15 years residing in Semnan, Iran in Amiralmoe menin hospital were tested for anti-HBs during 2009. Informed consent was obtained from all children and/or their parents or guardians who agreed to participate in the study. The questionnaire was completed about the child’s general data (e.g., family history of contact with HBV and knowledge about the possibility for the child to have any immunosuppressive disease, such as HIV, type 1 diabetes mellitus, or chronic renal failure).

We included immunocompetent participants without history of previous HBV infection. The participants were excluded from the study on the basis of the following criteria: (a) were not screened for serologic markers of HBV infection (HBsAg) before vaccination; (b) born to HBsAg carrier mothers; (c) had predisposing factors for any immunosuppressive disease such as HIV positive.

After blood sample collections, plasma samples were collected and tested for anti-HBs using enzyme-linked immunosorbent assay (ELISA) (Delaware Biotech Inc.)
Dover, DE, USA) following the manufacturer’s protocol.
The antigen and antibody formed a sandwich complex
with the conjugated antibodies with the peroxidase
(horseradish peroxidase) and the enzymatic activity was
detected with the specific chromogen/substrate 3,3’5,5’-
tetramethylbenzidine (TMB).
The TMB levels were quantified at 450 nm and the
concentrations of the anti-HBs were determined on the
standard curve. The levels of anti-HBs < 10 mIU/mL
were considered to be negative and samples showing
an anti-HBs titer ≥ 10 mIU/mL was considered protective [1].
The Chi-square test and Fisher’s exact test were used
with the SPSS 16 Package program (Chicago, IL, USA).
Data were presented as mean ± SD or, when indicated,
as an absolute number and percentage. Student’s t-test
was used for statistical analysis to compare the means
between the two groups.

Results
A total of 210 children were participated in this study.
Totally, 67 cases (32%) were under 5 years, 67 (32%) were
between 5 to 9 years old and 76 (36%) were more
than 10 years. The male to female ratio was 1. Distribution
of anti-HBs levels according to sex, age and duration
after vaccination are shown in Table 1. Eighty four
cases (80%) in the female group and 82 cases (78%) in
the male group had protective levels of anti-HBs > 10
mIU/mL, with no statistically significant difference in
anti-HBs positivity and genders (p = 0.735). Anti-HBs
positivity was seen in 87% of cases less than 5 years,
81% of cases between 5 and 10 years and 71% of cases
more than 10 years.
Protective antibody levels were detected in 88% of the
children less than 5 year after vaccination, decreased to
78% between 5 to 10 years after vaccination, and further
declined to 74% in 10 years after vaccination, respec-

Discussion
The immunity derived from the HBV vaccine was as-
essed by measuring the antibody in 210 children who
were vaccinated in a routine vaccination program in cen-
tral province of Iran, Semnan.
In our study, among 210 cases, 166 children (79%) had
antibodies levels ≥ 10 mIU/mL. Protective antibody lev-
els were detected in 88% of the children less than 5 year
after vaccination, 78% in cases between 5 to 10 years
after vaccination, and 74% in cases at 10 years after vac-
cination. Generally, 3-30% of vaccinated individuals
lost their protective anti-HBs titres five years after the
hepatitis B vaccination [8]. Long-term follow-up studies
demonstrated that antibodies might become negative in
15-50% among the vaccine responders within 5 to 10
years [9, 10].
According to several studies among healthy children
who had received a complete hepatitis B immunization
program, the protective titer of anti-HBs antibody > 5
years after the last dose were seen in 50-100% of indi-
viduals [7, 11-13]. It has been reported that the variabil-
ity in the anti-HBs antibody might be due to is the type
of vaccine used, the amount of antigen delivered and the
population immunized [14-17].
The HBV vaccination started in infants in two provinces
(Zanjan and Semnan) in 1989, and since 1993 the vac-
cination was introduced in the expanded program on immu-
nization in Iran. After implementation of HBV
vaccination in our country, the coverage has reached
an appropriate level 94% in 2005 compare with 62% in
1993 [18].
Jafarzadeh et al. found that 81.5% of children had pro-
tective levels of antibody [19] at five years after primary
hepatitis B immunization while 47.9% of children had
protective levels of antibody 10 years after primary vac-
cination [20].
In Aghakhani et al. study, protective antibody levels
were detected in 65% of children one year after vaccina-
tion, which declined significantly over time to 24% in 15
years after vaccination [21].

|                | Anti-HBs ≥ 10 mIU/mL | Anti-HBs < 10 mIU/mL | Total |
|----------------|----------------------|----------------------|-------|
|                | N        | %      | N        | %      | N      |
| Sex            |          |        |          |        |        |
| Male           | 82       | 78     | 23       | 22     | 105    |
| Female         | 84       | 80     | 21       | 20     | 105    |
| Age            |          |        |          |        |        |
| < 5 years      | 58       | 87     | 9        | 13     | 67     |
| 5-10 years     | 54       | 81     | 13       | 19     | 67     |
| ≥ 10 years     | 54       | 71     | 22       | 29     | 76     |
| Duration after vaccination |          |        |          |        |        |
| < 5 years      | 62       | 87     | 9        | 13     | 71     |
| 5-10 years     | 54       | 78     | 15       | 22     | 69     |
| ≥ 10 years     | 52       | 74     | 18       | 26     | 70     |
In Gilca et al. study, 88.2%, 86.4% and 76.7% of cases had a titer ≥ 10 IU/L after 5, 10 and 15 years post-vaccination [13].

In our study similar to other studies, no differences were observed between sex, age and anti-HBs titer following the vaccination [8, 21].

There are controversies over the long-term persistence of post vaccination immunity to hepatitis B. According to meta-analysis, protection which was provided by three or four doses of monovalent HB vaccine persists for at least two decades in the great majority of immunocompetent individuals and 3 doses of HB vaccine ensure a good protection against infection for up to 20 years [2], while some studies recommend a need for booster dose of vaccine in our country [20, 21]. Although a booster dose increases substantially anti-HBs titers, the clinical relevance of such an increase remains unknown.

In conclusion, the vaccination program has been proven effective in Semnan and immunological protection against HBV infection was found in the majority of children even more than 10 years after being vaccinated.

References

[1] Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol 2011;17:87-95.
[2] Poorolajal J, Mahmoudi M, Majdzadeh R, et al. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010;28:623-31.
[3] Fagundes GD, Tabalipa FdO, Silva Jd. Antibody levels in children after 10 years of vaccination against hepatitis B: a brazilian community-based study. Revista da Sociedade Brasileira de Medicina Tropical 2012;45:260-2.
[4] Alaviani SM, Hajjarizadeh B, Ahmadzad-Asl M, et al. Hepatitis B Virus infection in Iran: A systematic review. Hepat Mon 2008;8:281-94.
[5] Hollinger FB, Liang TJ. Hepatitis B virus. In: Fields Virology, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2001, pp. 2971-3036.
[6] Mahoney FJ, Kane M. Hepatitis B vaccine. Vaccines 1999;3:158-82.
[7] Boxall EH, Sira JA, El-Shuhkri N, et al. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004;190:1264-9.
[8] Alexandre KVF, Martins RMB, Souza MMd, et al. Brazilian hepatitis B vaccine: a six-year follow-up in adolescents. Memórias do Instituto Oswaldo Cruz 2012;107:1060-3.
[9] Huang LM, Chiang BL, Lee CY, et al. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999;29:954-9.
[10] Wu JS, Hwang L-Y, Goodman KJ, et al. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999;179:1319-25.
[11] FitzSimons D, François G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005;23:4158-66.
[12] McMahon BJ, Brudin DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Am Intern Med 2005;142:333-41.
[13] Gilca V, De Serres G, Boullanne N, et al. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine 2013;31:448-51.
[14] Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002;325:569.
[15] Nakao K, Hamasaki K, Wakihama N, et al. Analysis of anti-HBs levels in healthcare workers over 10 years following booster vaccination for hepatitis B virus. Vaccine 2003;21:3789-94.
[16] But DY-K, Lai C-L, Lim W-L, et al. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008;26:6587-91.
[17] AlFaleh F, AlShehri S, AlAnsari S, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect 2008;57:404-9.
[18] Alaviani SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 2007;16:403.
[19] Jafarzadeh A, Sajjadi S. Persistence of anti-HBs antibodies in healthy Iranian children vaccinated with recombinant hepatitis B vaccine and response to a booster dose. Acta Med Iranica 2005;43:79-84.
[20] Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad 2006;18:4-9.
[21] Aghakhani A, Banifazl M, Izadi N, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World J Pediatr 2011;7:358-60.